E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
To evaluate the feasibility of regionally reversing a rocuronium induced muscle relaxation and to determine the dose of sugammadex that is necessary to reach a train of four (TOF) ratio ≥ 0.9. To determine the time needed to regionally reverse rocuronium induced muscle relaxation to a TOF) ratio ≥ 0.9. To determine the effects of systemic muscle relaxation when the tourniquet is released
|
|
E.1.1.1 | Medical condition in easily understood language |
This trial will investigate the feasibility and dose necessary to reverse muscleparalysis during generalanaesthesia due to rocuronium but only regionally in one exsanguined arm of the patient. |
|
E.1.1.2 | Therapeutic area | Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the feasibility of regionally reversing a rocuronium induced muscle relaxation and to determine the dose of sugammadex that is necessary to reach a train of four (TOF) ratio ≥ 0.9.
|
|
E.2.2 | Secondary objectives of the trial |
To determine the time needed to regionally reverse rocuronium induced muscle relaxation to a TOF) ratio ≥ 0.9.
To determine the effects of systemic muscle relaxation when the tourniquet is released
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
We will include only adult (age 18-80 years) ASA 1-3 patients of an BMI between 18 and 30 that undergo elective surgery with the need of general anaesthesia and who will receive routine muscle relaxation with rocuronium. We will only include patients that undergo procedures that provide access to both arms to simultaneously measure the TOF. |
|
E.4 | Principal exclusion criteria |
We will exclude patients with a known allergy against sugammadex as well as patients with severe renal impairment since sugammadex is contraindicated or not recommended in these patients. Patients in whom pregnancy cannot be excluded will be excluded. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary endpoint of the first sequence is the mean dose necessary to regionally reverse the rocuronium induced muscle relaxation to a TOF level ≥ 0.9. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
After completion of sequence 1 according to the study protocol |
|
E.5.2 | Secondary end point(s) |
Secondary outcome parameter is the effect of the release of the tourniquet on the systemic muscle relaxation, as represented by the TOF of the not exsanguined arm. Primary endpoint of the second sequence is the time needed to provide a regional reversal of the rocuronium induced muscle relaxation to a TOF level ≥ 0.9 with the mean dose calculated at sequence one. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
After completion of sequence one and two according to the study protocol |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
This trial is a prospective, sequential, interventional, single centre pilot study. Phase 2. |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |